Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating ...

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 5.30%, which has investors questioning if this is right time to buy.

BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH), announced today the ...

Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.

Inhibikase Therapeutics (IKT) announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.Stay Ahead of ...

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical ...

BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH), announced today the appointment ...

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small ...